Cambridge, Massachusetts-based Tango Therapeutics, a biotechnology company focused on targeted cancer therapies, has secured $60 million in Series B financing. Boxer Capital of the Tavistock Group led the round with participation from Cormorant Asset Management and Casdin Capital.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: